Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/10/2018
SIETES contiene 92566 citas

 
 
 1 a 20 de 4404 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Clozapine ou autres neuroleptiques: occlusions intestinales mortelles. Prescrire 2018;38:511. [Ref.ID 102760]
2. Cita con resumen
Anónimo. Nétupitant + palonosétron et prévention des vomissements chimio-induits. Prescrire 2018;38:176-7. [Ref.ID 102587]
3. Cita con resumen
Anónimo. Éluxadoline et troubles fonctionnels intestinaux récurrents. Prescrire 2018;38:91-5. [Ref.ID 102580]
4.Enlace a cita original Cita con resumen
Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint PK, Grossi CM, Mattishent K, Bennett K, Campbell NL, Boustani M, Robinson L, Brayne C, Matthews FE, Savva GM. Anticholinergic drugs and risk of dementia: case-control study. BMJ 2018;361:25 de abril. [Ref.ID 102571]
5.Enlace a cita original Cita con resumen
Abrahami D, Douros A, Yin H, Yu OHY, Renoux C, Bitton A, Azoulay L. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018;360:21 de marzo. [Ref.ID 102562]
6.Enlace a cita original Cita con resumen
Bonovas S, Nikolopoulos GK, Lytras T, Fiorino G, Peyrin-Biroulet L, Danese S. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis . Br J Clin Pharmacol 2018;84:febrero. [Ref.ID 102533]
7. Cita con resumen
Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurology 2017:5 de septiembre. [Ref.ID 102058]
8. Cita con resumen
Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med 2017;177:1308-15. [Ref.ID 102042]
9. Cita con resumen
Anónimo. Ivacaftor et mucoviscidose (suite). Prescrire 2017;37:566-8. [Ref.ID 102040]
10. Cita con resumen
Anónimo. Ivacaftor + lumacaftor et mucoviscidose. Prescrire 2017;37:569-71. [Ref.ID 102039]
11. Cita con resumen
Wallerstedt SM, Fastbom J, Linke J, Vitols S. Long-term use of proton pump inhibitors and prevalence of disease - and drug-related reasons for gastroprotection — A cross-sectional population-based study. Pharmacoepidemiol Drug Saf 2017;26:9-16. [Ref.ID 101946]
12. Cita con resumen
Wei L, Ratnayake L, Phillips G, McGuigan CC, Morant SV, Flynn RW, Mackenzie IS, MacDonald TM. Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study. Br J Clin Pharmacol 2017;83:1298-308. [Ref.ID 101942]
13. Cita con resumen
Persson M, Cnattingius S, Villamor E, Söderling J, Pasternak B, Stephansson O, Neovius M. Risk of major congenital malformations in relation to maternal overweight and obesity severity: cohort study of 1.2 million singletons. BMJ 2017;357:j2563. [Ref.ID 101639]
14. Cita con resumen
Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med 2017;177:784-91. [Ref.ID 101618]
15.Enlace a cita original Cita con resumen
Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, Rojas-Fernández C, Walsh K, Welch V, Moayyedi P. Deprescribing proton pump inhibitors. Evidence-based clinical practice guideline. Canadian Family Physician - Le Médecin de Famille Canadien 2017;63:354-64. [Ref.ID 101592]
16. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
17. Cita con resumen
Wang Y-F, Chen Y-T, Luo J-C, Chen T-J, Wu J-C, Wang S-J. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. The American Journal of Gastroenterology 2017;112:1084-93. [Ref.ID 101543]
18.Enlace a cita original Cita con resumen
DREAMS Trial Collaborators and West Midlands Research Collaborative. Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial). BMJ 2017;357:j1455. [Ref.ID 101540]
19. Cita con resumen
Jensen AK, Simonsen JE, Ethelberg S. Use of proton pump inhibitors and the risk of listeriosis: a nationwide registry-based case-control study. Clin Infect Dis 2017;64:845-51. [Ref.ID 101519]
20. Cita con resumen
Huizinga P, Kluytmans-van den Bergh M, van Rijen M, Willemsen I, van't Veer N, Kluytmans J. Proton pump inhibitor use is associated with extended-spectrum ß-lactamase-producing enterobacteriaceae rectal carriage at hospital admission: a cross-sectional study. Clin Infect Dis 2017;64:361-3. [Ref.ID 101508]
Seleccionar todas
 
 1 a 20 de 4404 siguiente >>